Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:44:54 EDT Thu 18 Apr 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:BLUE
- BLUEBIRD BIO INC -
http://www.bluebirdbio.com/
21:44:54 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
BLUE
- Q
5.5
0.9501
·
0.99
2.2
0.953
-0.0103
-1.1
6,531.6
5,735
6,398
0.965
1.01
0.92
5.53 0.879
19:58:51
Apr 11
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Up
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 6398
More trades...
Time ET
Ex
Price
Change
Volume
19:58:51
Q
0.95
-0.0133
25
19:46:34
Q
0.9529
-0.0104
14
19:13:30
Q
0.951
-0.0123
8
18:41:30
Q
0.953
-0.0103
20
18:40:56
Q
0.96
-0.0033
10
18:40:09
Q
0.96
-0.0033
10
18:19:54
Q
0.975
0.0117
2
18:04:56
Q
0.95
-0.0133
100
17:46:06
Q
0.9528
-0.0105
200
17:45:59
Q
0.95
-0.0133
100
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2024-04-11 08:00
U:BLUE
News Release
200
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-26 07:01
U:BLUE
News Release
200
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
2024-03-25 16:05
U:BLUE
News Release
200
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
2024-03-18 08:00
U:BLUE
News Release
200
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
2024-03-11 08:00
U:BLUE
News Release
200
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
2024-01-08 08:00
U:BLUE
News Release
200
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
2024-01-02 08:00
U:BLUE
News Release
200
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-19 21:41
U:BLUE
News Release
200
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
2023-12-18 16:01
U:BLUE
News Release
200
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
2023-12-10 12:02
U:BLUE
News Release
200
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for Ž ²-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
2023-12-09 11:31
U:BLUE
News Release
200
Long-term Follow-up Data From bluebird ¢ € ™s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
2023-12-08 13:01
U:BLUE
News Release
200
bluebird bio Details Plans for the Commercial Launch of LYFGENIA ¢ „ ¢ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
2023-12-08 12:35
U:BLUE
News Release
200
bluebird bio Announces FDA Approval of LYFGENIA ¢ „ ¢ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
2023-11-07 07:00
U:BLUE
News Release
200
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
2023-11-02 09:37
U:BLUE
News Release
200
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
2023-10-30 08:00
U:BLUE
News Release
200
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
2023-10-24 08:00
U:BLUE
News Release
200
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
2023-09-05 16:05
U:BLUE
News Release
200
bluebird bio Announces September Investor Events
2023-08-16 07:00
U:BLUE
News Release
200
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
2023-08-08 07:00
U:BLUE
News Release
200
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress